Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
Richard M. Lawn, … , Ashley M. Vaughan, John F. Oram
Richard M. Lawn, … , Ashley M. Vaughan, John F. Oram
Published October 15, 1999
Citation Information: J Clin Invest. 1999;104(8):R25-R31. https://doi.org/10.1172/JCI8119.
View: Text | PDF
Rapid Publication

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway

  • Text
  • PDF
Abstract

The ABC1 transporter was identified as the defect in Tangier disease by a combined strategy of gene expression microarray analysis, genetic mapping, and biochemical studies. Patients with Tangier disease have a defect in cellular cholesterol removal, which results in near zero plasma levels of HDL and in massive tissue deposition of cholesteryl esters. Blocking the expression or activity of ABC1 reduces apolipoprotein-mediated lipid efflux from cultured cells, and increasing expression of ABC1 enhances it. ABC1 expression is induced by cholesterol loading and cAMP treatment and is reduced upon subsequent cholesterol removal by apolipoproteins. The protein is incorporated into the plasma membrane in proportion to its level of expression. Different mutations were detected in the ABC1 gene of 3 unrelated patients. Thus, ABC1 has the properties of a key protein in the cellular lipid removal pathway, as emphasized by the consequences of its defect in patients with Tangier disease.

Authors

Richard M. Lawn, David P. Wade, Michael R. Garvin, Xingbo Wang, Karen Schwartz, J. Gordon Porter, Jeffrey J. Seilhamer, Ashley M. Vaughan, John F. Oram

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
(a) Antisense inhibition of ABC1 reduces cholesterol efflux. Normal huma...
(a) Antisense inhibition of ABC1 reduces cholesterol efflux. Normal human skin fibroblasts were labeled with [3H]cholesterol as described in Methods. Cells were scrape-loaded in the presence of either 30 μM standard control Morpholino oligonucleotide (antisense complement of a β-globin thalassemic mRNA) or 30 μM ABC1 antisense Morpholino oligonucleotide, or were mock-loaded by scraping in the absence of oligonucleotide. Apo A-I–mediated efflux was measured after 12 hours as in the legend to Figure 2. Results presented are the mean ± SEM of 3 separate experiments, normalized to the value for apo A-I–specific efflux in the absence of oligonucleotide in each experiment. (b) Overexpression of ABC1 enhances apo A-I–mediated cholesterol efflux. Parental RAW 264.7 cells and clonal lines 3, 5, and 6 that had been stably transfected with a vector-expressing human ABC1 were cholesterol-loaded and labeled by incubation for 24 hours with 0.5 μCi/mL [3H]cholesterol and 50 μg/mL acetylated LDL, and efflux was measured as described in Methods. Results presented are the mean ± SEM of 3 separate experiments normalized to the value for apo A-I–specific efflux from parental RAW 264.7 cells within each experiment.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts